Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
Public ClinicalTrials.gov record NCT06350123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Multicenter, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination With Dapagliflozin Compared With Dapagliflozin in Patients With Chronic Kidney Disease and Albuminuria
Study identification
- NCT ID
- NCT06350123
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 324 participants
Conditions and interventions
Conditions
Interventions
- Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg Drug
- Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg Drug
- Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2024
- Primary completion
- May 8, 2025
- Completion
- May 8, 2025
- Last update posted
- Jun 25, 2026
2024 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Sheffield | Alabama | 35660 | — |
| Research Site | Glendale | California | 91206 | — |
| Research Site | Waterbury | Connecticut | 06708 | — |
| Research Site | Hialeah | Florida | 33012 | — |
| Research Site | Miami Lakes | Florida | 33014 | — |
| Research Site | Annapolis | Maryland | 21401 | — |
| Research Site | New Bern | North Carolina | 28562 | — |
| Research Site | El Paso | Texas | 79935 | — |
| Research Site | Houston | Texas | 77079 | — |
| Research Site | Houston | Texas | 77099 | — |
| Research Site | San Antonio | Texas | 78212 | — |
| Research Site | Ogden | Utah | 84405 | — |
| Research Site | Salt Lake City | Utah | 84115 | — |
| Research Site | Salt Lake City | Utah | 84124 | — |
| Research Site | Norfolk | Virginia | 23504 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06350123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06350123 live on ClinicalTrials.gov.